Pharmacogenomics, theranostics and personalized medicine - The complexities of clinical trials: Challenges in the developing world

Applied and Translational Genomics

Volumn 2, Issue 1, 2013, Pages 17-21

  Limaye, Nimita ^a  

^a TATA CONSULTANCY SERVICES   (India)

Author keywords

Biobanking; Clinical trials; India; Personalized medicine; Pharmacogenomics; Theranostics

Indexed keywords

CETUXIMAB; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IMATINIB; IRINOTECAN; TRASTUZUMAB; WARFARIN;

AFRICAN AMERICAN; AMERICAN INDIAN; ARTICLE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONTINUING EDUCATION; DEVELOPING COUNTRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; ENVIRONMENTAL FACTOR; FINANCIAL MANAGEMENT; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; GENE TECHNOLOGY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEART FAILURE; HUMAN; INDIA; MEDICAL RESEARCH; METHODOLOGY; MICROARRAY ANALYSIS; MICROARRAY KIT; PATIENT EDUCATION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RESEARCH ETHICS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84890241018     PISSN: 22120661     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atg.2013.05.002     Document Type: Review

References (41)

1. Adams J.U. Pharmacogenomics and personalized medicine. Nature Education 2008, 1(1). (http://www.nature.com/scitable/topicpage/pharmacogenomics-and-personalized-medicine-643).
2. Banerjeee M. Is pharmacogenomics a reality? Challenges and opportunities for India. Indian Journal of Human Genetics 2011, 17.1:S1-S3.
3. Branca M. The new, new pharmacogenomics. BioIT World 2002, (http://www.bio-itworld.com/archive/090902/pharma.html).
4. Brandi M.L., Eric A., Ann D., Willard D., Domnique E., et al. Challenges faced in the integration of pharmacogenetics/genomics into drug development. Journal of Pharmacogenomics & Pharmacoproteomics 2012, 3:108.
5. Chew J. Big pharma's mantra: fail early, fail fast http://seekingalpha.com/author/jason-chew/comment/1109600.
6. Davies K. The $ 1,000,000 genome interpretation. BioIT World 2010, (http://www.bio-itworld.com/2010/issues/sept-oct/physicans.html).
7. Dey S. Government tightening clinical trial norms http://www.business-standard.com/article/economy-policy/govt-tightening-clinical-trial-norms-112080602002_1.html.
8. Dhar B., Joseph R. Foreign direct investment, intellectual property rights and technology transfer. The North-south and the South-South Dimension. Background Paper No. 6, UNCTAD 2012.
9. Dolled-Filhart M.P., Lordemann A., Dahl W., Haraksingh R.R., Ou-Yang C.-W., Lin J.C.-H. Personalizing rare disease research. How genomics is revolutionizing the diagnosis and treatment of rare disease. Personalized Medicine 2012, 9(8):805-819.
10. Frueh F. Personalized medicine: what is it? How will it affect healthcare?. Paper presented at: 11th Annual FDA Science Forum 2005, (Washington, DC. http://www.fda.gov/downloads/Drugs ScienceResearch/ResearchAreas/Pharmacogenetics/ucm085716).
11. Gitig D. Increasing percentages of new drugs are failing phase II and III trials. Highlight HEALTH 2012, (http://www.highlighthealth.com/health-news/increasing-percentages-of-new-drugs-are-failing-phase-ii-and-iii-trials/).
12. Global Biobanks Market to Reach US$22.3 Billion by 2017, According to a New Report by Global Industry Analysts, Inc. http://www.prweb.com/releases/biobanks_cord_blood_banks/stem_cell_banks/prweb8831399.htm.
13. Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products EMA/CHMP/37646/2009 2011.
14. Guidelines to develop proposals in the area of Pharmacogenomics Department of biotechnology, ministry of science & technology http://dbtindia.nic.in/uniquepage.asp?id_pk=41.
15. Haberman A. Overcoming phase II attrition problem. Genetic Engineering and Biotechnology News 2009, 29.14.
16. http://online.wsj.com/article/SB10001424052970204707104578090863855010972.html.
17. http://www.affymetrix.com/estore/browse/products.jsp?productId=131412#1_1.
18. http://www.pharmaadme.org/joomla/.
19. http://www.visiongain.com/Report/973/Pharma-Clinical-Trial-Services-World-Market-2013-2023.
20. http://www.scientificamerican.com/article.cfm?id=race-in-a-bottle&print=true(9/21/2009.
21. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC30039490/.
22. ICMR sets up task force on pharmacogenomics The Hindu http://www.thehindu.com/todays-paper/tp-national/tp-tamilnadu/icmr-sets-up-task-force-on-pharmacogenomics/article575518.ece?textsize=small&test=2.
23. India's R&D-The Future Forward BioSpectrum http://http://www.biospectrumindia.com/biospecindia/news/156732/indias-r-d-the-future-forward.
24. Jahanara P. India steps closer to personalized medicine. BioSpectrum 2010, (http://www.biospectrumindia.com/biospecindia/news/155942/india-steps-closer-personalized-medicine).
25. Lazarou J., Bruce H.P., Paul N.C. Incidence of adverse drug reactions in hospitalized patients - a meta-analysis of prospective studies. JAMA 1998, 279(15):1200-1205.
26. List of approved drugs from 0.101.12 till to date http://cdsco.nic.in/listofdrugapprovedmain.html.
27. Mapes M. Cancer clinical trial hurdles. Oncology street http://oncologystreet.com/index.php/clinical-trial-capsule/1-cancer-clinical-trials-hurdles.
28. Mc Donagh E.M., Whirl-Carrillo M., Garten Y., Altman R.B., Klein T.E. From pharmacogenomics knowledge acquisition to clinical applications: the PharrmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers in Medicine 2011, 5(6):795-806.
29. Murarka V. Personalized medicine picks up pace in India. BioSpectrum 2012, (http://www.biospectrumasia.com/biospectrum/analysis/3147/one-size-fit-anymore).
30. Nair S.R. Personalized medicine: striding from genes to medicines. Perspectives in Clinical Research 2010, 1(4):146-150.
31. New drugs approved with clinical trial on decline: Minister http://www.taxindiaonline.com/RC2/inside2.php3?filename=bnews_detail.php3&newsid=15712.
32. Perkel J. Finding the true $1000 genome. BioTechniques 2013, 54.2:71-74.
33. Ravishankar D. Biobanking has attractive prospects in Asia. BioSpectrum Asia 2012, (http://www.biospectrumasia.com/biospectrum/opinion/1750/biobanking-attractive-prospects-asia).
34. Recovery Act Investment Enables TCGA to Map 20 Cancers The Cancer Genome Atlas http://cancergenome.nih.gov/newsevents/newsannouncements/news_9_30_2009.
35. Reich D., Kumarasamy T., Patterson N., Price A.L., Singh L. Reconstructing Indian population history. Nature 2009, 461:489-494.
36. Scott C.T., Caulfield T., Borgelt E., Illes J. Personal medicine - the new banking crisis. Nature Biotechnology 2012, 30(2):141-147.
37. The Future of Biobanks: Regulation, Ethics, Investment and the Humanization of Drug Discovery http://www.reportlinker.com/p0115252/The-Future-of-Biobanks-Regulation-ethics-investment-and-the-humanization-of-drug-discovery.html.
38. Translational Medicine Paradigms in Clinical Trials Clinical research society http://www.clinicalresearchsociety.org/translationalmedicine/.
39. Vyas H. Now your saliva will tell you about the health of your heart http://articles.timesofindia.indiatimes.com/2012-08-08/science/33099919_1_heart-disease-risk-factors-heart-patients.
40. Webb D. When foods and drugs collide - studies expose interactions between certain foods and medications. Todays Dietitian 2010, 12.12:26.
41. Zanger U.M. Pharmacogenetics - challenges and opportunities ahead. Frontiers in Pharmacology 2010, 1:112.